July 23rd 2025
Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outc...
1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Ma...
1.5 Credits / Ophthalmology/Optometry
View More
Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes...
1.5 Credits / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)
1.5 Credit / Ophthalmology/Optometry
View More
Leveraging Novel Therapies to Transform Demodex Blepharitis Care
1.5 Credit / Ophthalmology/Optometry
View More
Cardinal Health Report Sees 2022 as “Turning Point” for Biosimilars
February 8th 2022The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”
FDA Official Addresses Unanswered Questions About Interchangeable Biosimilars
November 10th 2021Sarah Yim, MD, provided a point-by-point overview of the FDA's efforts to clarify the role of the interchangeable biosimilar designation, improve communication with manufacturers, and pay for biosimilar regulatory reviews.
Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201
October 6th 2021Positive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).
Cardinal Health Biosimilars Expert Discusses Dynamics of Byooviz Launch
September 24th 2021The first ranibizumab biosimilar (Byooviz) has potential to alleviate financial burden associated with retinal conditions, but may not be the only new approval for ophthalmology treatment in 2022, explains Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars for Cardinal Health.
AAO Reacts to Ranibizumab Biosimilar Approval
September 23rd 2021The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.